Clinical Trial

A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-25
Trial Details
NCT Number NCT07406035
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Psoriatic Arthritis
Enrollment 156 participants
Start Date 2026-07-16
Primary Completion 2027-08 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-24